centessa.comCrawled Oct 18, 2026
Centessa Pharmaceuticals uses its LockBody technology platform to develop immuno-oncology treatments for cancer, addressing unmet needs in efficacy and safety.
Centessa Pharmaceuticals is developing orexin receptor 2 (OX2R) agonists for neuroscience disorders, aiming to provide transformative treatment options.
Centessa Pharmaceuticals develops therapies for excessive daytime sleepiness, cognitive deficits, and fatigue linked to neurological disorders.
Centessa Pharmaceuticals is developing orexin receptor 2 (OX2R) agonists for sleep-wake disorders, including narcolepsy and idiopathic hypersomnia.
Centessa Pharmaceuticals, a subsidiary of Eli Lilly and Company, hires across key areas including biostatistics, clinical development, and regulatory affairs.
Charlene Stoudt joined Centessa in October 2024 as Senior Vice President, Clinical Development Operations.
Gregory Weinhoff, MD, MBA, serves as Chief Business Officer of Centessa Pharmaceuticals, previously holding the role of Chief Financial Officer and co-founding Arvelle Therapeutics BV.
Harris Rotman, PhD, joined Centessa Pharmaceuticals in July 2022 as Senior Vice President of Regulatory Affairs, with over 20 years of pharmaceutical industry experience and expertise in regulatory agencies and investigational development.
Karen Anderson joined Centessa Pharmaceuticals in November 2022 as Chief People Officer, with over 25 years of experience in human resources across biotechnology, technology, and healthcare industries.
Centessa Pharmaceuticals focuses on discovering and developing transformational medicines, including first-in-class and best-in-class treatments for neuroscience indications.
Centessa Pharmaceuticals pursues its Orexin Receptor 2 Agonist Program to deliver treatment options for sleep-wake, neurological, and neuropsychiatric disorders.
Centessa Pharmaceuticals conducts clinical trials to evaluate investigational medical products, aiming to achieve regulatory approval and provide patient access to treatments.
